LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Twist Bioscience Corp

Closed

SectorHealthcare

47.39 -3.64

Overview

Share price change

24h

Current

Min

46.88

Max

50.52

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+9.54% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

309M

2.9B

Previous open

51.03

Previous close

47.39

News Sentiment

By Acuity

50%

50%

149 / 352 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

11 Feb 2026, 23:47 UTC

Hot Stocks

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 Feb 2026, 22:59 UTC

Earnings
Acquisitions, Mergers, Takeovers

Grab Holdings to Buy U.S.-Based Stash Financial

11 Feb 2026, 23:54 UTC

Earnings

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 Feb 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 Feb 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 Feb 2026, 23:49 UTC

Earnings

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 Feb 2026, 23:45 UTC

Earnings

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 Feb 2026, 23:42 UTC

Earnings

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 Feb 2026, 23:41 UTC

Earnings

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 Feb 2026, 23:40 UTC

Earnings

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 Feb 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 Feb 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 Feb 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 Feb 2026, 22:59 UTC

Earnings

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 Feb 2026, 22:59 UTC

Earnings

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 Feb 2026, 22:59 UTC

Earnings

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 Feb 2026, 22:58 UTC

Earnings

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 Feb 2026, 22:57 UTC

Earnings

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 Feb 2026, 22:54 UTC

Earnings

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 Feb 2026, 22:53 UTC

Earnings

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 Feb 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 Feb 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 Feb 2026, 22:23 UTC

Earnings

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 Feb 2026, 22:22 UTC

Earnings

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 Feb 2026, 22:22 UTC

Earnings

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 Feb 2026, 22:19 UTC

Earnings

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 Feb 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 Feb 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 Feb 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 Feb 2026, 22:16 UTC

Earnings

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

9.54% upside

12 Months Forecast

Average 52 USD  9.54%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

149 / 352 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat